ORYZON receives approval from MHRA to initiate Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia in the United Kingdom
The First Specific LSD1 Inhibitor to Enter the Clinic.
ORYZON, a biopharmaceutical company with a strong focus on epigenetics, has announced that has received the approval from the British Drug Agency (MHRA) on January 15th, 2014 to initiate a Phase I/IIA clinical trial of ORY-1001, a novel and highly selective LSD1 inhibitor, in patients with relapsed or refractory acute leukemia in the United Kingdom.
The company got the approval from the Spanish Drug Agency (AEMPS) a few weeks ago. This first-in-human trial is currently open at the Hospital Vall d’Hebron in Barcelona, Spain and additional study sites in Spain and in the United Kingdom will be incorporated shortly.
